#nct_id	eligibility_type	criterion	label	term	ner_score	concepts	tree_numbers	nel_score
NCT04346355	inclusion	Real time polymerase chain reaction (PCR) diagnosis of Sars-CoV2 infection	word_scores:clinical_variable	real time polymerase chain reaction	1.000	Real-Time Polymerase Chain Reaction	E05.393.620.500.706	1.000
NCT04346355	inclusion	Real time polymerase chain reaction (PCR) diagnosis of Sars-CoV2 infection	word_scores:chronic_disease	sars-cov2 infection	1.000	COVID-19	C01.925	1.000
NCT04346355	inclusion	Hospitalization due to clinical / instrumental diagnosis (high resolution chest CT scan or chest x-ray or pulmonary ultrasound)	word_scores:treatment	chest ct scan	1.000
NCT04346355	inclusion	Hospitalization due to clinical / instrumental diagnosis (high resolution chest CT scan or chest x-ray or pulmonary ultrasound)	word_scores:treatment	chest x-ray	1.000
NCT04346355	inclusion	Hospitalization due to clinical / instrumental diagnosis (high resolution chest CT scan or chest x-ray or pulmonary ultrasound)	word_scores:treatment	pulmonary ultrasound	1.000
NCT04346355	inclusion	Presence of acute respiratory distress syndrome with arterial partial pressure of oxygen / fraction of inspired oxygen (PaO2 / FiO2) between 200 and 300 mm/Hg	word_scores:chronic_disease	acute respiratory distress syndrome	1.000	Respiratory Distress Syndrome, Adult	C08.381.840|C08.618.840	1.000
NCT04346355	inclusion	Presence of acute respiratory distress syndrome with arterial partial pressure of oxygen / fraction of inspired oxygen (PaO2 / FiO2) between 200 and 300 mm/Hg	word_scores:clinical_variable	arterial partial pressure oxygen / fraction inspired oxygen	1.000
NCT04346355	inclusion	Presence of exaggerated inflammatory response defined by the presence of at least 1 of the following criteria: At least one body temperature measurement >38° C in the past two days	word_scores:clinical_variable	body temperature measurement	1.000
NCT04346355	inclusion	Presence of exaggerated inflammatory response defined by the presence of at least 1 of the following criteria: Serum CRP greater than or equal to 10 mg/dl	word_scores:clinical_variable	serum crp	1.000
NCT04346355	exclusion	Patients with respiratory distress syndrome with arterial partial pressure of oxygen / fraction of inspired oxygen (PaO2 / FiO2) <200 mm/Hg or	word_scores:chronic_disease	respiratory distress syndrome	1.000	Respiratory Distress Syndrome, Adult	C08.381.840|C08.618.840	1.000
NCT04346355	exclusion	Patients with respiratory distress syndrome with arterial partial pressure of oxygen / fraction of inspired oxygen (PaO2 / FiO2) <200 mm/Hg or	word_scores:clinical_variable	arterial partial pressure oxygen / fraction inspired oxygen	1.000
NCT04346355	exclusion	Patients in non-invasive ventilation or	word_scores:treatment	non-invasive ventilation	1.000	Noninvasive Ventilation	E02.041.625.591|E02.880.820.657	1.000
NCT04346355	exclusion	Patients in invasive ventilation or presence of shock or presence of concomitant organ failure that requires admission to the Intensive Care Unit	word_scores:treatment	invasive ventilation	1.000	Noninvasive Ventilation	E02.041.625.591|E02.880.820.657	0.850
NCT04346355	exclusion	Patients in invasive ventilation or presence of shock or presence of concomitant organ failure that requires admission to the Intensive Care Unit	word_scores:chronic_disease	organ failure	1.000
NCT04346355	exclusion	Severe heart and kidney failure	word_scores:chronic_disease	severe heart	1.000	Heart	A07.541	1.000
NCT04346355	exclusion	Severe heart and kidney failure	word_scores:chronic_disease	kidney failure	1.000	Kidney Failure	C12.777.419.780|C13.351.968.419.780	1.000
NCT04346355	exclusion	Pregnant or breastfeeding patient	word_scores:pregnancy	pregnant	1.000	Pregnancy	G08.686.784.769	1.000
NCT04346355	exclusion	Known hypersensitivity to TCZ or its excipients	word_scores:allergy_name	tcz	1.000
NCT04346355	exclusion	Patient being treated with immuno-depressors or anti-rejection drugs	word_scores:treatment	immuno-depressors	1.000
NCT04346355	exclusion	Patient being treated with immuno-depressors or anti-rejection drugs	word_scores:treatment	anti-rejection drugs	1.000
NCT04346355	exclusion	Known active infections or other clinical conditions that contraindicate TCZ and cannot be treated or resolved according to the physician's judgment	word_scores:chronic_disease	active infections	1.000
NCT04346355	exclusion	Known active infections or other clinical conditions that contraindicate TCZ and cannot be treated or resolved according to the physician's judgment	word_scores:treatment	tcz	1.000
NCT04346355	exclusion	glutamate-pyruvate transaminase (GPT) or glutamine oxaloacetic transaminase (GOT) > 5 times the upper limit of the norm	word_scores:clinical_variable	glutamate-pyruvate transaminase	1.000
NCT04346355	exclusion	glutamate-pyruvate transaminase (GPT) or glutamine oxaloacetic transaminase (GOT) > 5 times the upper limit of the norm	word_scores:clinical_variable	glutamine oxaloacetic transaminase	1.000	Aspartate Aminotransferases	D08.811.913.477.700.225	0.765
NCT04346355	exclusion	Neutrophils <500 /mmc	word_scores:clinical_variable	neutrophils	1.000	Neutrophils	A11.118.637.415.583|A11.627.340.583|A11.733.689|A15.145.229.637.415.583|A15.382.490.315.583|A15.382.680.689	1.000
NCT04346355	exclusion	Platelets <50.000 /mmc	word_scores:clinical_variable	platelets	1.000	Blood Platelets	A11.118.188|A15.145.229.188	1.000
NCT04346355	exclusion	Diverticulitis or intestinal perforation	word_scores:chronic_disease	diverticulitis	1.000	Diverticulitis	C06.405.205.282.500	1.000
NCT04346355	exclusion	Diverticulitis or intestinal perforation	word_scores:chronic_disease	intestinal perforation	1.000	Intestinal Perforation	C06.405.469.557	1.000
NCT04346355	exclusion	Suspicion of latent tuberculosis	word_scores:chronic_disease	latent tuberculosis	1.000	Latent Tuberculosis	C01.150.252.410.040.552.846.122	1.000
NCT04344951	inclusion	For women of childbearing age, they should use or be willing to use a double contraceptive method during the study. A urine pregnancy test to exclude pregnancy will be performed prior to study initiation	word_scores:gender	women	1.000	Women	M01.975	1.000
NCT04344951	inclusion	For women of childbearing age, they should use or be willing to use a double contraceptive method during the study. A urine pregnancy test to exclude pregnancy will be performed prior to study initiation	word_scores:contraception_consent	use be willing to use a double contraceptive method	1.000
NCT04344951	inclusion	For women of childbearing age, they should use or be willing to use a double contraceptive method during the study. A urine pregnancy test to exclude pregnancy will be performed prior to study initiation	word_scores:pregnancy	pregnancy	1.000	Pregnancy	G08.686.784.769	1.000
NCT04344951	inclusion	Upper respiratory or lower respiratory tract infection, as in Annexes II and III respectively	word_scores:chronic_disease	upper respiratory	1.000	Upper Respiratory Tract Infections	C01.748|C08.730	1.000
NCT04344951	inclusion	Upper respiratory or lower respiratory tract infection, as in Annexes II and III respectively	word_scores:chronic_disease	lower respiratory tract infection	1.000
NCT04344951	inclusion	Positive respiratory secretion test for SARS-CoV-2 virus by molecular techniques or positive blood IgM titers	word_scores:treatment	molecular techniques	1.000
NCT04344951	exclusion	Serum AST values greater than 5 times the upper normal range	word_scores:clinical_variable	serum ast values	1.000
NCT04344951	exclusion	QTc interval in rest electrocardiogram greater than 500msecs	word_scores:clinical_variable	qtc interval	1.000
NCT04344951	exclusion	Pregnancy or lactation. Urgent pregnancy test to exclude pregnancy before inclusion in the study	word_scores:pregnancy	pregnancy	1.000	Pregnancy	G08.686.784.769	1.000
NCT04344951	exclusion	Pregnancy or lactation. Urgent pregnancy test to exclude pregnancy before inclusion in the study	word_scores:pregnancy	pregnancy	1.000	Pregnancy	G08.686.784.769	1.000
NCT04344951	exclusion	Pregnancy or lactation. Urgent pregnancy test to exclude pregnancy before inclusion in the study	word_scores:pregnancy	pregnancy	1.000	Pregnancy	G08.686.784.769	1.000
NCT04344444	inclusion	Positive SARS-CoV-2 testing or consistent clinical syndrome (based on clinical picture e.g. characteristic infiltrates on chest x-ray, laboratory findings, and with agreement by two physicians) in patients under investigation (PUIs)	word_scores:chronic_disease	clinical syndrome	1.000
NCT04344444	inclusion	Positive SARS-CoV-2 testing or consistent clinical syndrome (based on clinical picture e.g. characteristic infiltrates on chest x-ray, laboratory findings, and with agreement by two physicians) in patients under investigation (PUIs)	word_scores:treatment	chest x-ray	1.000
NCT04344444	inclusion	Oxygen saturation of >94% on room air with defined risk factors (Table 1) consistent with moderate disease OR oxygen saturation of < 94% on room air consistent with severe disease	word_scores:clinical_variable	oxygen saturation	1.000
NCT04344444	inclusion	Oxygen saturation of >94% on room air with defined risk factors (Table 1) consistent with moderate disease OR oxygen saturation of < 94% on room air consistent with severe disease	word_scores:clinical_variable	oxygen saturation	1.000
NCT04344444	exclusion	QTc greater than 450 milliseconds on screening EKG	word_scores:clinical_variable	qtc	1.000
NCT04344444	exclusion	Pregnant or lactating women	word_scores:pregnancy	pregnant	1.000	Pregnancy	G08.686.784.769	1.000
NCT04344444	exclusion	Pregnant or lactating women	word_scores:gender	women	1.000	Women	M01.975	1.000
NCT04344444	exclusion	Inability to take oral pills or inability to use a feeding tube	word_scores:treatment	oral pills	1.000
NCT04344444	exclusion	Inability to take oral pills or inability to use a feeding tube	word_scores:contraception_consent	inability to use a feeding tube	1.000
NCT04344444	exclusion	use of azithromycin or hydroxychloroquine within 30 days prior to admission	word_scores:treatment	azithromycin	1.000	Azithromycin	D02.540.576.500.992.050	1.000
NCT04344444	exclusion	use of azithromycin or hydroxychloroquine within 30 days prior to admission	word_scores:treatment	hydroxychloroquine	1.000	Hydroxychloroquine	D03.633.100.810.050.180.350	1.000
NCT04344080	inclusion	confirmed COVID-19 disease	word_scores:chronic_disease	covid-19 disease	1.000	COVID-19	C01.925	1.000
NCT04344080	inclusion	refractory shock with need for norepinephrine ≥ 0.2 μg/kg/min for MAP ≥ 65 mmHg	word_scores:clinical_variable	norepinephrine	1.000	Norepinephrine	D02.033.100.291.502|D02.092.063.480|D02.092.211.215.746|D02.092.311.830|D02.455.426.559.389.657.166.175.830	1.000
NCT04344080	inclusion	refractory shock with need for norepinephrine ≥ 0.2 μg/kg/min for MAP ≥ 65 mmHg	word_scores:clinical_variable	map	1.000
NCT04344080	inclusion	IL6 ≥ 500 ng/l	word_scores:clinical_variable	il6	1.000	Interleukin-6	D12.644.276.374.465.224|D12.776.467.374.465.202|D23.529.374.465.224	1.000
NCT04344080	inclusion	Indication for CRRT or ECMO	word_scores:treatment	indication	1.000
NCT04344080	inclusion	Indication for CRRT or ECMO	word_scores:treatment	crrt	1.000
NCT04344080	inclusion	Indication for CRRT or ECMO	word_scores:treatment	ecmo	1.000	Extracorporeal Membrane Oxygenation	E02.880.301|E04.292.451	1.000
NCT04344080	exclusion	Liver cirrhosis Child Pugh C	word_scores:clinical_variable	liver cirrhosis child pugh c	1.000
NCT04344080	exclusion	pregnancy or breastfeeding	word_scores:pregnancy	pregnancy	1.000	Pregnancy	G08.686.784.769	1.000
NCT04344080	exclusion	participation in another interventional trial	word_scores:treatment	interventional trial	1.000
NCT04344015	inclusion	Prior diagnosis of COVID-19 documented by a laboratory test approved by the FDA	word_scores:chronic_disease	covid-19	1.000	COVID-19	C01.925	1.000
NCT04344015	inclusion	Male donors, never-pregnant female donors, or previously pregnant female donors negative for HLA antibodies	word_scores:gender	male	1.000	Men	M01.390	1.000
NCT04344015	inclusion	Male donors, never-pregnant female donors, or previously pregnant female donors negative for HLA antibodies	word_scores:gender	female	1.000	Women	M01.975	1.000
NCT04344015	inclusion	Male donors, never-pregnant female donors, or previously pregnant female donors negative for HLA antibodies	word_scores:pregnancy	pregnant	1.000	Pregnancy	G08.686.784.769	1.000
NCT04344015	inclusion	Male donors, never-pregnant female donors, or previously pregnant female donors negative for HLA antibodies	word_scores:gender	female	1.000	Women	M01.975	1.000
NCT04344015	inclusion	Male donors, never-pregnant female donors, or previously pregnant female donors negative for HLA antibodies	word_scores:treatment	hla antibodies	1.000
NCT04344015	exclusion	Failure to pass standard volunteer blood donor screening criteria required by the Jefferson Blood Donor Center and the FDA	word_scores:clinical_variable	jefferson blood donor center	1.000
NCT04344015	exclusion	Female donors with HLA antibodies (per FDA requirements for convalescent plasma donors)	word_scores:gender	female	1.000	Women	M01.975	1.000
NCT04344015	exclusion	Female donors with HLA antibodies (per FDA requirements for convalescent plasma donors)	word_scores:treatment	hla antibodies	1.000
NCT04344015	exclusion	Inadequate venous access for phlebotomy	word_scores:treatment	phlebotomy	1.000	Phlebotomy	E01.370.225.998.110.625|E02.800.558|E04.665.150.625|E05.200.998.110.625	1.000
NCT04344015	exclusion	Currently pregnant	word_scores:pregnancy	pregnant	1.000	Pregnancy	G08.686.784.769	1.000
NCT04343989	inclusion	Confirmed COVID-19 disease (by Cobas SARS-CoV-2 real time RT-PCR using nasopharyngeal swab sample, or equivalent test available to be performed by the NYU Langone clinical laboratory). Effort will be made to have the confirmatory test result <72 hours prior to enrollment however given overall clinical demand this may not be feasible in all cases	word_scores:chronic_disease	covid-19 disease	1.000	COVID-19	C01.925	1.000
NCT04343989	inclusion	Respiratory failure manifesting as: Acute Respiratory Distress Syndrome (defined by a P/F ratio of <200), OR SpO2 < 90% on 4L (actual or expected given higher O2 requirement) OR increasing O2 requirements over 24 hours, PLUS 2 or more of the following predictors for severe disease	word_scores:chronic_disease	respiratory failure	1.000	Respiratory Failure	C08.618.846	1.000
NCT04343989	inclusion	Respiratory failure manifesting as: Acute Respiratory Distress Syndrome (defined by a P/F ratio of <200), OR SpO2 < 90% on 4L (actual or expected given higher O2 requirement) OR increasing O2 requirements over 24 hours, PLUS 2 or more of the following predictors for severe disease	word_scores:chronic_disease	acute respiratory distress syndrome	1.000	Respiratory Distress Syndrome, Adult	C08.381.840|C08.618.840	1.000
NCT04343989	inclusion	Respiratory failure manifesting as: Acute Respiratory Distress Syndrome (defined by a P/F ratio of <200), OR SpO2 < 90% on 4L (actual or expected given higher O2 requirement) OR increasing O2 requirements over 24 hours, PLUS 2 or more of the following predictors for severe disease	word_scores:clinical_variable	p/f ratio	1.000
NCT04343989	inclusion	Respiratory failure manifesting as: Acute Respiratory Distress Syndrome (defined by a P/F ratio of <200), OR SpO2 < 90% on 4L (actual or expected given higher O2 requirement) OR increasing O2 requirements over 24 hours, PLUS 2 or more of the following predictors for severe disease	word_scores:clinical_variable	spo2	1.000
NCT04343989	inclusion	CRP > 35 mg/L Ferritin > 500 ng/mL D-dimer > 1 mcg/L Neutrophil-Lymphocyte Ratio > 4 LDH > 200 U/L Increase in troponin in patient w/out known cardiac disease	word_scores:clinical_variable	crp	1.000
NCT04343989	inclusion	CRP > 35 mg/L Ferritin > 500 ng/mL D-dimer > 1 mcg/L Neutrophil-Lymphocyte Ratio > 4 LDH > 200 U/L Increase in troponin in patient w/out known cardiac disease	word_scores:clinical_variable	ferritin	1.000	Ferritins	D12.776.157.427.249|D12.776.556.579.249	1.000
NCT04343989	inclusion	CRP > 35 mg/L Ferritin > 500 ng/mL D-dimer > 1 mcg/L Neutrophil-Lymphocyte Ratio > 4 LDH > 200 U/L Increase in troponin in patient w/out known cardiac disease	word_scores:clinical_variable	d-dimer	1.000
NCT04343989	inclusion	CRP > 35 mg/L Ferritin > 500 ng/mL D-dimer > 1 mcg/L Neutrophil-Lymphocyte Ratio > 4 LDH > 200 U/L Increase in troponin in patient w/out known cardiac disease	word_scores:clinical_variable	neutrophil-lymphocyte ratio	1.000
NCT04343989	inclusion	CRP > 35 mg/L Ferritin > 500 ng/mL D-dimer > 1 mcg/L Neutrophil-Lymphocyte Ratio > 4 LDH > 200 U/L Increase in troponin in patient w/out known cardiac disease	word_scores:clinical_variable	ldh	1.000
NCT04343989	inclusion	CRP > 35 mg/L Ferritin > 500 ng/mL D-dimer > 1 mcg/L Neutrophil-Lymphocyte Ratio > 4 LDH > 200 U/L Increase in troponin in patient w/out known cardiac disease	word_scores:chronic_disease	cardiac disease	1.000	Heart Diseases	C14.280	1.000
NCT04343989	inclusion	Women of childbearing potential must be willing and able to use at least one highly effective contraceptive method for a period of 5 months following the study drug administration. In the context of this study, an effective method is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly such as	word_scores:gender	women	1.000	Women	M01.975	1.000
NCT04343989	inclusion	Women of childbearing potential must be willing and able to use at least one highly effective contraceptive method for a period of 5 months following the study drug administration. In the context of this study, an effective method is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly such as	word_scores:contraception_consent	willing able to use one highly effective contraceptive method	1.000
NCT04343989	inclusion	combined (estrogen and progestogen containing) hormonal contraception combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, or transdermal)	word_scores:treatment	estrogen	1.000	Estrogens	D27.505.696.399.472.277	1.000
NCT04343989	inclusion	combined (estrogen and progestogen containing) hormonal contraception combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, or transdermal)	word_scores:treatment	progestogen	1.000	Progestins	D27.505.696.399.472.858	0.889
NCT04343989	inclusion	combined (estrogen and progestogen containing) hormonal contraception combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, or transdermal)	word_scores:treatment	estrogen	1.000	Estrogens	D27.505.696.399.472.277	1.000
NCT04343989	inclusion	combined (estrogen and progestogen containing) hormonal contraception combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, or transdermal)	word_scores:treatment	progestogen	1.000	Progestins	D27.505.696.399.472.858	0.889
NCT04343989	inclusion	combined (estrogen and progestogen containing) hormonal contraception combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, or transdermal)	word_scores:treatment	oral	1.000	Oral Stage	F01.752.747.722.626|F02.739.794.793.626	1.000
NCT04343989	inclusion	combined (estrogen and progestogen containing) hormonal contraception combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, or transdermal)	word_scores:contraception_consent	intravaginal	1.000
NCT04343989	inclusion	combined (estrogen and progestogen containing) hormonal contraception combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, or transdermal)	word_scores:treatment	transdermal	1.000
NCT04343989	inclusion	progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)	word_scores:contraception_consent	progestogen-only hormonal contraception	1.000
NCT04343989	inclusion	progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)	word_scores:contraception_consent	oral	1.000	Oral Stage	F01.752.747.722.626|F02.739.794.793.626	1.000
NCT04343989	inclusion	progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)	word_scores:contraception_consent	injectable	1.000	Contraceptives, Injections, Consent	CC01.01.01.04	0.875
NCT04343989	inclusion	progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)	word_scores:contraception_consent	implantable	1.000	Contraceptives, Implant, Consent	CC01.03.02	1.000
NCT04343989	inclusion	intrauterine device (IUD)	word_scores:contraception_consent	intrauterine device	1.000	Intrauterine Devices, Consent	CC01.03.01	1.000
NCT04343989	inclusion	intrauterine hormone-releasing system (IUS)	word_scores:treatment	intrauterine hormone-releasing system	1.000
NCT04343989	inclusion	bilateral tubal occlusion	word_scores:chronic_disease	bilateral tubal occlusion	1.000
NCT04343989	inclusion	Men must be willing to use a double-barrier contraception from enrollment until at 5 months after the last dose of study drug, if not abstinent	word_scores:contraception_consent	willing to use a double-barrier contraception	1.000
NCT04343989	inclusion	Men must be willing to use a double-barrier contraception from enrollment until at 5 months after the last dose of study drug, if not abstinent	word_scores:treatment	study drug	1.000
NCT04343989	exclusion	Evidence of irreversible injury deemed non-survivable even if the pulmonary failure recovers (for example severe anoxic brain injury)	word_scores:chronic_disease	pulmonary failure	1.000
NCT04343989	exclusion	Evidence of irreversible injury deemed non-survivable even if the pulmonary failure recovers (for example severe anoxic brain injury)	word_scores:chronic_disease	anoxic brain injury	1.000
NCT04343989	exclusion	Known active inflammatory bowel disease	word_scores:chronic_disease	inflammatory bowel disease	1.000	Inflammatory Bowel Diseases	C06.405.205.731|C06.405.469.432	1.000
NCT04343989	exclusion	Known active, untreated diverticulitis	word_scores:chronic_disease	diverticulitis	1.000	Diverticulitis	C06.405.205.282.500	1.000
NCT04343989	exclusion	Known untreated bacteremia	word_scores:chronic_disease	bacteremia	1.000	Bacteremia	C01.150.252.100|C01.757.100|C23.550.470.790.500.100	1.000
NCT04343989	exclusion	Pregnancy. (The protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis)	word_scores:pregnancy	pregnancy	1.000	Pregnancy	G08.686.784.769	1.000
NCT04343989	exclusion	Pregnancy. (The protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis)	word_scores:pregnancy	pregnant	1.000	Pregnancy	G08.686.784.769	1.000
NCT04343989	exclusion	Pregnancy. (The protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis)	word_scores:pregnancy	pregnancy	1.000	Pregnancy	G08.686.784.769	1.000
NCT04343989	exclusion	Known hypersensitivity to the clazakizumab	word_scores:allergy_name	clazakizumab	1.000
NCT04342182	inclusion	Patients with PCR confirmed COVID disease	word_scores:treatment	pcr	1.000	Polymerase Chain Reaction	E05.393.620.500	1.000
NCT04342182	inclusion	Patients with PCR confirmed COVID disease	word_scores:chronic_disease	covid disease	1.000	COVID-19	C01.925	1.000
NCT04342182	inclusion	A history of COVID infection that was documented by PCR	word_scores:chronic_disease	covid infection	1.000	COVID-19	C01.925	1.000
NCT04342182	inclusion	A negative screening for irregular antibodies	word_scores:treatment	irregular antibodies	1.000
NCT04342182	inclusion	Donors will be restricted to those who had a symptomatic COVID infection defined as documented fever 38.0 or higher C for at least 48 hours	word_scores:chronic_disease	symptomatic covid infection	1.000	COVID-19	C01.925	1.000
NCT04342182	inclusion	Written informed consent regarding the plasmapheresis procedure	word_scores:treatment	plasmapheresis procedure	1.000
NCT04342182	exclusion	Patient in which a "no ICU admission" or "no invasive ventilation" restriction was implemented at the time of screening for the study	word_scores:treatment	invasive ventilation restriction	1.000
NCT04342182	exclusion	Weight <45kg	word_scores:clinical_variable	weight	1.000	Weights	E05.978	0.750
NCT04342182	exclusion	Medical history of heart failure	word_scores:chronic_disease	heart failure	1.000	Heart Failure	C14.280.434	1.000
NCT04342182	exclusion	History of transfusion with red blood cells, platelets or plasma	word_scores:treatment	transfusion red blood cells	1.000
NCT04342182	exclusion	History of transfusion with red blood cells, platelets or plasma	word_scores:clinical_variable	platelets	1.000	Blood Platelets	A11.118.188|A15.145.229.188	1.000
NCT04342182	exclusion	History of transfusion with red blood cells, platelets or plasma	word_scores:treatment	plasma	1.000	Plasma	A12.207.152.693|A12.207.270.695|A15.145.693	1.000
NCT04342182	exclusion	Born as a female person. The reason for this is a higher incidence of transfusion related acute lung injury (TRALI) after plasma transfusion from a female donor	word_scores:gender	female	1.000	Women	M01.975	1.000
NCT04342182	exclusion	Born as a female person. The reason for this is a higher incidence of transfusion related acute lung injury (TRALI) after plasma transfusion from a female donor	word_scores:chronic_disease	acute lung injury	1.000	Acute Lung Injury	C08.381.520.500	1.000
NCT04342182	exclusion	Born as a female person. The reason for this is a higher incidence of transfusion related acute lung injury (TRALI) after plasma transfusion from a female donor	word_scores:treatment	plasma transfusion	1.000
NCT04342182	exclusion	Born as a female person. The reason for this is a higher incidence of transfusion related acute lung injury (TRALI) after plasma transfusion from a female donor	word_scores:gender	female donor	1.000
NCT04341389	inclusion	Able to understand the content of informed consent and willing to sign the informed consent	word_scores:language_fluency	able to understand content informed consent willing to sign informed consent	1.000
NCT04341389	inclusion	Negative in HIV diagnostic test	word_scores:chronic_disease	hiv	1.000	HIV|HIV Infections	B04.820.650.589.650.350|C01.778.640.400|C01.925.782.815.616.400|C01.925.813.400|C20.673.480	1.000
NCT04341389	inclusion	Negative in serum antibodies (IgG and IgM) screening of COVID-19	word_scores:clinical_variable	serum antibodies	1.000
NCT04341389	inclusion	Negative in serum antibodies (IgG and IgM) screening of COVID-19	word_scores:chronic_disease	covid-19	1.000	COVID-19	C01.925	1.000
NCT04341389	inclusion	Axillary temperature ≤37.0°C	word_scores:clinical_variable	axillary temperature	1.000
NCT04341389	exclusion	Family history of seizure, epilepsy, brain or mental disease	word_scores:chronic_disease	seizure	1.000	Seizures	C10.597.742|C23.888.592.742	1.000
NCT04341389	exclusion	Family history of seizure, epilepsy, brain or mental disease	word_scores:chronic_disease	epilepsy	1.000	Epilepsy	C10.228.140.490	1.000
NCT04341389	exclusion	Family history of seizure, epilepsy, brain or mental disease	word_scores:chronic_disease	brain	1.000	Brain	A08.186.211	1.000
NCT04341389	exclusion	Family history of seizure, epilepsy, brain or mental disease	word_scores:chronic_disease	mental disease	1.000
NCT04341389	exclusion	Subject allergic to any component of the investigational vaccine, or a more severe allergic reaction and history of allergies in the past	word_scores:treatment	investigational vaccine	1.000
NCT04341389	exclusion	Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months	word_scores:gender	woman	1.000	Women	M01.975	1.000
NCT04341389	exclusion	Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months	word_scores:pregnancy	pregnant	1.000	Pregnancy	G08.686.784.769	1.000
NCT04341389	exclusion	Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months	word_scores:pregnancy	pregnancy	1.000	Pregnancy	G08.686.784.769	1.000
NCT04341389	exclusion	Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months	word_scores:pregnancy	become pregnant	1.000	Pregnancy	G08.686.784.769	1.000
NCT04341389	exclusion	Any acute fever disease or infections	word_scores:chronic_disease	acute fever disease	1.000
NCT04341389	exclusion	Any acute fever disease or infections	word_scores:chronic_disease	infections	1.000	Infections	C01	1.000
NCT04341389	exclusion	History of SARS	word_scores:chronic_disease	sars	1.000	Severe Acute Respiratory Syndrome	C01.748.730|C01.925.782.600.550.200.750|C08.730.730	1.000
NCT04341389	exclusion	Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease	word_scores:chronic_disease	major congenital defects	1.000
NCT04341389	exclusion	Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease	word_scores:chronic_disease	chronic illness	1.000	Chronic Disease	C23.550.291.500	1.000
NCT04341389	exclusion	Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease	word_scores:chronic_disease	asthma	1.000	Asthma	C08.127.108|C08.381.495.108|C08.674.095|C20.543.480.680.095	1.000
NCT04341389	exclusion	Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease	word_scores:chronic_disease	diabetes	1.000	Diabetes Mellitus	C18.452.394.750|C19.246	1.000
NCT04341389	exclusion	Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease	word_scores:chronic_disease	thyroid disease	1.000	Thyroid Diseases	C19.874	1.000
NCT04341389	exclusion	Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc	word_scores:chronic_disease	cardiovascular diseases	1.000	Cardiovascular Diseases	C14	1.000
NCT04341389	exclusion	Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc	word_scores:chronic_disease	arrhythmia	1.000	Arrhythmias, Cardiac	C14.280.067|C23.550.073	1.000
NCT04341389	exclusion	Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc	word_scores:chronic_disease	conduction block	1.000
NCT04341389	exclusion	Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc	word_scores:chronic_disease	myocardial infarction	1.000	Myocardial Infarction	C14.280.647.500|C14.907.585.500|C23.550.513.355.750|C23.550.717.489.750	1.000
NCT04341389	exclusion	Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc	word_scores:chronic_disease	severe hypertension	1.000	Hypertension	C14.907.489	1.000
NCT04341389	exclusion	Hereditary angioneurotic edema or acquired angioneurotic edema	word_scores:chronic_disease	hereditary angioneurotic edema	1.000	Angioedemas, Hereditary	C14.907.079.500|C16.320.798.500.500|C17.800.862.945.066.500|C20.543.480.904.066.500|C20.673.795.500.500	1.000
NCT04341389	exclusion	Hereditary angioneurotic edema or acquired angioneurotic edema	word_scores:chronic_disease	acquired angioneurotic edema	1.000
NCT04341389	exclusion	Urticaria in last one year	word_scores:chronic_disease	urticaria	1.000	Urticaria	C17.800.862.945|C20.543.480.904	1.000
NCT04341389	exclusion	Platelet disorder or other bleeding disorder may cause injection contraindication	word_scores:chronic_disease	platelet disorder	1.000	Blood Platelet Disorders	C15.378.140	1.000
NCT04341389	exclusion	Platelet disorder or other bleeding disorder may cause injection contraindication	word_scores:chronic_disease	bleeding disorder	1.000	Feeding Disorders	F03.400	0.800
NCT04341389	exclusion	Faint at the sight of needles	word_scores:treatment	faint	1.000
NCT04341389	exclusion	Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months	word_scores:treatment	immunodepressant	1.000
NCT04341389	exclusion	Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months	word_scores:treatment	corticosteroids	1.000	Adrenal Cortex Hormones	D06.472.040	1.000
NCT04341389	exclusion	Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months	word_scores:treatment	antianaphylaxis treatment	1.000
NCT04341389	exclusion	Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months	word_scores:treatment	cytotoxic treatment	1.000	Antibiotics, Cytotoxic	D27.505.954.248.106	1.000
NCT04341389	exclusion	Prior administration of attenuated vaccine in last 1 month	word_scores:treatment	attenuated vaccine	1.000	Vaccines, Attenuated	D20.215.894.811	0.938
NCT04341389	exclusion	Prior administration of inactivated vaccine in last 14 days	word_scores:treatment	inactivated vaccine	1.000	Vaccines, Inactivated	D20.215.894.830	0.941
NCT04341389	exclusion	Current anti-tuberculosis prophylaxis or therapy	word_scores:treatment	anti-tuberculosis prophylaxis	1.000
NCT04341389	exclusion	Current anti-tuberculosis prophylaxis or therapy	word_scores:treatment	therapy	1.000	Therapeutics	E02	1.000
NCT04341389	exclusion	According to the judgement of investigator,various medical, psychological, social or other conditions, those could affect the subjects to sign informed consent	word_scores:chronic_disease	psychological	1.000
NCT04340557	inclusion	Confirmed COVID-19 positive test result	word_scores:chronic_disease	covid-19	1.000	COVID-19	C01.925	1.000
NCT04340557	inclusion	Mild to moderate respiratory disease defined by oxygen requirement of at least 2 L/min to maintain oxygen saturation level ≥92%	word_scores:chronic_disease	respiratory disease	1.000
NCT04340557	inclusion	Mild to moderate respiratory disease defined by oxygen requirement of at least 2 L/min to maintain oxygen saturation level ≥92%	word_scores:clinical_variable	oxygen saturation level	1.000
NCT04340557	inclusion	Systolic blood pressure ≥ 110 mmHg	word_scores:clinical_variable	systolic blood pressure	1.000
NCT04340557	inclusion	Access to an electronic device that is able to access DocuSign® online and email for consenting	word_scores:technology_access	access to an electronic device	1.000
NCT04340557	inclusion	Able to read/write/speak English or Spanish fluently	word_scores:language_fluency	able to read/write/speak english spanish fluently	1.000
NCT04340557	inclusion	Negative pregnancy test for women of childbearing potential	word_scores:pregnancy	negative pregnancy	1.000	Pregnancy	G08.686.784.769	1.000
NCT04340557	inclusion	Negative pregnancy test for women of childbearing potential	word_scores:gender	women	1.000	Women	M01.975	1.000
NCT04340557	exclusion	Severe allergy to any ARB or ACE-inhibitor, including angioedema	word_scores:allergy_name	arb	1.000
NCT04340557	exclusion	Severe allergy to any ARB or ACE-inhibitor, including angioedema	word_scores:treatment	ace-inhibitor	1.000
NCT04340557	exclusion	Severe allergy to any ARB or ACE-inhibitor, including angioedema	word_scores:chronic_disease	angioedema	1.000	Angioedema	C14.907.079|C17.800.862.945.066|C20.543.480.904.066	1.000
NCT04340557	exclusion	Home meds include any kind of ACE inhibitor or ARB	word_scores:treatment	ace inhibitor	1.000	Angiotensin-Converting Enzyme Inhibitors	D27.505.519.389.745.085	0.909
NCT04340557	exclusion	Home meds include any kind of ACE inhibitor or ARB	word_scores:treatment	arb	1.000
NCT04340557	exclusion	SBP <110 mmHg	word_scores:clinical_variable	sbp	1.000
NCT04340557	exclusion	Acute Kidney Injury (50% reduction in GFR from baseline at admission to any time during treatment in the study treatment arm)	word_scores:clinical_variable	acute kidney injury	1.000	Acute Kidney Injury	C12.777.419.780.050|C13.351.968.419.780.050	1.000
NCT04340557	exclusion	Acute Kidney Injury (50% reduction in GFR from baseline at admission to any time during treatment in the study treatment arm)	word_scores:treatment	treatment	1.000	Therapeutics	E02	1.000
NCT04340557	exclusion	Hyperkalemia >5.0 mmol/L at baseline or any time during treatment in the study treatment arm	word_scores:clinical_variable	hyperkalemia	1.000	Hyperkalemia	C18.452.950.396	1.000
NCT04340557	exclusion	Hyperkalemia >5.0 mmol/L at baseline or any time during treatment in the study treatment arm	word_scores:treatment	treatment	1.000	Therapeutics	E02	1.000
NCT04340557	exclusion	Creatinine Clearance < 30 ml/min at baseline or any time during treatment in the study treatment arm	word_scores:clinical_variable	creatinine clearance	1.000
NCT04340557	exclusion	Creatinine Clearance < 30 ml/min at baseline or any time during treatment in the study treatment arm	word_scores:treatment	treatment	1.000	Therapeutics	E02	1.000
NCT04340050	inclusion	Prior diagnosis of COVID-19 documented by a laboratory test (confirmed)	word_scores:chronic_disease	covid-19	1.000	COVID-19	C01.925	1.000
NCT04340050	inclusion	Female donors who have never been pregnant, previously pregnant female donors negative for HLA antibodies (HLA screening), or male donors	word_scores:gender	female	1.000	Women	M01.975	1.000
NCT04340050	inclusion	Female donors who have never been pregnant, previously pregnant female donors negative for HLA antibodies (HLA screening), or male donors	word_scores:pregnancy	never been pregnant	1.000
NCT04340050	inclusion	Female donors who have never been pregnant, previously pregnant female donors negative for HLA antibodies (HLA screening), or male donors	word_scores:pregnancy	previously pregnant	1.000
NCT04340050	inclusion	Female donors who have never been pregnant, previously pregnant female donors negative for HLA antibodies (HLA screening), or male donors	word_scores:gender	female	1.000	Women	M01.975	1.000
NCT04340050	inclusion	Female donors who have never been pregnant, previously pregnant female donors negative for HLA antibodies (HLA screening), or male donors	word_scores:treatment	hla antibodies	1.000
NCT04340050	inclusion	Female donors who have never been pregnant, previously pregnant female donors negative for HLA antibodies (HLA screening), or male donors	word_scores:gender	male	1.000	Men	M01.390	1.000
NCT04340050	inclusion	Must have laboratory-confirmed COVID-19	word_scores:chronic_disease	covid-19	1.000	COVID-19	C01.925	1.000
NCT04340050	inclusion	Must have severe or immediately life-threatening COVID-19	word_scores:chronic_disease	covid-19	1.000	COVID-19	C01.925	1.000
NCT04340050	inclusion	Severe defined as dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or lung infiltrates > 50% within 24 to 48 hours	word_scores:chronic_disease	dyspnea	1.000	Dyspnea	C08.618.326|C23.888.852.371	1.000
NCT04340050	inclusion	Severe defined as dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or lung infiltrates > 50% within 24 to 48 hours	word_scores:clinical_variable	respiratory frequency	1.000
NCT04340050	inclusion	Severe defined as dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or lung infiltrates > 50% within 24 to 48 hours	word_scores:clinical_variable	blood oxygen saturation	1.000
NCT04340050	inclusion	Severe defined as dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or lung infiltrates > 50% within 24 to 48 hours	word_scores:clinical_variable	partial pressure arterial oxygen to fraction inspired oxygen ratio	1.000
NCT04340050	inclusion	Severe defined as dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or lung infiltrates > 50% within 24 to 48 hours	word_scores:clinical_variable	lung infiltrates	1.000
NCT04340050	inclusion	Life-threatening defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Lower priority should be given to patients with septic shock or multiple organ dysfunction or failure since their disease may have progressed to a point where they are not able to benefit from convalescent plasma therapy	word_scores:chronic_disease	respiratory failure	1.000	Respiratory Failure	C08.618.846	1.000
NCT04340050	inclusion	Life-threatening defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Lower priority should be given to patients with septic shock or multiple organ dysfunction or failure since their disease may have progressed to a point where they are not able to benefit from convalescent plasma therapy	word_scores:chronic_disease	septic shock	1.000	Shock, Septic	C01.757.800|C23.550.470.790.500.800|C23.550.835.900.712	1.000
NCT04340050	inclusion	Life-threatening defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Lower priority should be given to patients with septic shock or multiple organ dysfunction or failure since their disease may have progressed to a point where they are not able to benefit from convalescent plasma therapy	word_scores:chronic_disease	multiple organ dysfunction	1.000
NCT04340050	inclusion	Life-threatening defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Lower priority should be given to patients with septic shock or multiple organ dysfunction or failure since their disease may have progressed to a point where they are not able to benefit from convalescent plasma therapy	word_scores:chronic_disease	septic shock	1.000	Shock, Septic	C01.757.800|C23.550.470.790.500.800|C23.550.835.900.712	1.000
NCT04340050	inclusion	Life-threatening defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Lower priority should be given to patients with septic shock or multiple organ dysfunction or failure since their disease may have progressed to a point where they are not able to benefit from convalescent plasma therapy	word_scores:chronic_disease	multiple organ dysfunction	1.000
NCT04340050	inclusion	Life-threatening defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Lower priority should be given to patients with septic shock or multiple organ dysfunction or failure since their disease may have progressed to a point where they are not able to benefit from convalescent plasma therapy	word_scores:treatment	convalescent plasma therapy	1.000
NCT04340050	inclusion	Of note, eIND application for each recipient subject will need to be approved before administration of convalescent plasma	word_scores:treatment	convalescent plasma	1.000
NCT04340050	exclusion	Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period	word_scores:gender	female	1.000	Women	M01.975	1.000
NCT04340050	exclusion	Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period	word_scores:pregnancy	positive pregnancy	1.000	Pregnancy	G08.686.784.769	1.000
NCT04340050	exclusion	Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period	word_scores:pregnancy	planning to become pregnant/breastfeed	1.000
NCT04340050	exclusion	Contraindication to transfusion or history of prior reactions to transfusion blood products	word_scores:allergy_name	transfusion blood products	1.000
NCT04340050	exclusion	Patients currently enrolled in other drug trials that preclude investigational treatment with anti-SARS-CoV-2 convalescent plasma	word_scores:treatment	investigational treatment	1.000	Therapies, Investigational	E02.931	1.000
NCT04348032	inclusion	Patients were diagnosed with ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by previous pathology, and the pathological type was non-mucinous adenocarcinoma.There were previous surgical wax preservation	word_scores:cancer	ovarian cancer	1.000	Ovary Cancer	C04.588.322.455|C13.351.500.056.630.705|C13.351.937.418.685|C19.344.410|C19.391.630.705	1.000
NCT04348032	inclusion	Patients were diagnosed with ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by previous pathology, and the pathological type was non-mucinous adenocarcinoma.There were previous surgical wax preservation	word_scores:cancer	fallopian tube cancer	1.000	Fallopian Tube Cancer	C04.588.945.418.365|C13.351.500.056.390.390|C13.351.937.418.365	1.000
NCT04348032	inclusion	Patients were diagnosed with ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by previous pathology, and the pathological type was non-mucinous adenocarcinoma.There were previous surgical wax preservation	word_scores:cancer	primary peritoneal cancer	1.000
NCT04348032	inclusion	Patients were diagnosed with ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by previous pathology, and the pathological type was non-mucinous adenocarcinoma.There were previous surgical wax preservation	word_scores:cancer	non-mucinous adenocarcinoma	1.000
NCT04348032	inclusion	Initial platinum-resistant relapse, the recurrence time was less than 6 months after the last chemotherapy	word_scores:treatment	chemotherapy	1.000	Drug Therapy	E02.319	1.000
NCT04348032	inclusion	Complicated with malignant pleural effusion or ascites, or with recurrent lesions that can be evaluated clinically	word_scores:chronic_disease	ascites	1.000	Ascites	C23.550.081	1.000
NCT04348032	inclusion	ECOG physical status score 0 or 1	word_scores:clinical_variable	ecog physical status score	1.000
NCT04348032	inclusion	The expected survival time is ≥ 4 months	word_scores:clinical_variable	expected survival time	1.000
NCT04348032	inclusion	In the previous treatment, there was no antivascular targeted therapy	word_scores:treatment	previous treatment	1.000
NCT04348032	inclusion	In the previous treatment, there was no antivascular targeted therapy	word_scores:treatment	antivascular targeted therapy	1.000
NCT04348032	inclusion	Patients without pleural effusion or ascites should be confirmed by CT or MRI according to the standard of RECIST1.1 version, requiring the patient to have at least one measurable focus as the target focus. If the target focus is a lymph node with a short diameter of more than 1.5 cm, and the target focus is not suitable for surgical treatment, the target focus has not received radiotherapy or relapsed in the radiotherapy field	word_scores:chronic_disease	pleural effusion	1.000	Pleural Effusion	C08.528.652	1.000
NCT04348032	inclusion	Patients without pleural effusion or ascites should be confirmed by CT or MRI according to the standard of RECIST1.1 version, requiring the patient to have at least one measurable focus as the target focus. If the target focus is a lymph node with a short diameter of more than 1.5 cm, and the target focus is not suitable for surgical treatment, the target focus has not received radiotherapy or relapsed in the radiotherapy field	word_scores:chronic_disease	ascites	1.000	Ascites	C23.550.081	1.000
NCT04348032	inclusion	Patients without pleural effusion or ascites should be confirmed by CT or MRI according to the standard of RECIST1.1 version, requiring the patient to have at least one measurable focus as the target focus. If the target focus is a lymph node with a short diameter of more than 1.5 cm, and the target focus is not suitable for surgical treatment, the target focus has not received radiotherapy or relapsed in the radiotherapy field	word_scores:treatment	ct	1.000
NCT04348032	inclusion	Patients without pleural effusion or ascites should be confirmed by CT or MRI according to the standard of RECIST1.1 version, requiring the patient to have at least one measurable focus as the target focus. If the target focus is a lymph node with a short diameter of more than 1.5 cm, and the target focus is not suitable for surgical treatment, the target focus has not received radiotherapy or relapsed in the radiotherapy field	word_scores:treatment	magnetic resonance imaging	1.000	Magnetic Resonance Imaging	E01.370.350.825.500	1.000
NCT04348032	inclusion	Patients without pleural effusion or ascites should be confirmed by CT or MRI according to the standard of RECIST1.1 version, requiring the patient to have at least one measurable focus as the target focus. If the target focus is a lymph node with a short diameter of more than 1.5 cm, and the target focus is not suitable for surgical treatment, the target focus has not received radiotherapy or relapsed in the radiotherapy field	word_scores:treatment	surgical treatment	1.000
NCT04348032	inclusion	Patients without pleural effusion or ascites should be confirmed by CT or MRI according to the standard of RECIST1.1 version, requiring the patient to have at least one measurable focus as the target focus. If the target focus is a lymph node with a short diameter of more than 1.5 cm, and the target focus is not suitable for surgical treatment, the target focus has not received radiotherapy or relapsed in the radiotherapy field	word_scores:treatment	radiotherapy	1.000	Radiotherapy	E02.815	1.000
NCT04348032	inclusion	Patients without pleural effusion or ascites should be confirmed by CT or MRI according to the standard of RECIST1.1 version, requiring the patient to have at least one measurable focus as the target focus. If the target focus is a lymph node with a short diameter of more than 1.5 cm, and the target focus is not suitable for surgical treatment, the target focus has not received radiotherapy or relapsed in the radiotherapy field	word_scores:treatment	radiotherapy	1.000	Radiotherapy	E02.815	1.000
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: neutrophil count ≥ 1.5x109 /L	word_scores:clinical_variable	neutrophil count	1.000
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: platelet count ≥ 100x109 PG L	word_scores:clinical_variable	platelet count	1.000	Platelet Count	E01.370.225.500.195.107.740|E01.370.225.625.107.700|E01.370.225.625.625.625|E05.200.500.195.107.740|E05.200.625.107.700|E05.200.625.625.625|E05.242.195.107.740|G04.140.107.740|G09.188.105.700	1.000
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: hemoglobin ≥ 9g/dL (blood transfusion is allowed to achieve or maintain this target)	word_scores:clinical_variable	hemoglobin	1.000	Hemoglobin E|Hemoglobins	D12.776.124.400|D12.776.124.400.463.375|D12.776.422.316.762|D12.776.422.316.762.426.375	1.000
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: total bilirubin<1.5 normal limit (ULN)	word_scores:clinical_variable	bilirubin<1 5 normal limit	1.000
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: glutamic oxaloacetic transaminase (AST), glutamic pyruvic transaminase (ALT)<2.5xULN, which is allowed<5xULN in patients with liver metastasis	word_scores:clinical_variable	glutamic oxaloacetic transaminase	1.000	Aspartate Aminotransferases	D08.811.913.477.700.225	1.000
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: glutamic oxaloacetic transaminase (AST), glutamic pyruvic transaminase (ALT)<2.5xULN, which is allowed<5xULN in patients with liver metastasis	word_scores:clinical_variable	glutamic pyruvic transaminase	1.000	Alanine Transaminase	D08.811.913.477.700.100	1.000
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: glutamic oxaloacetic transaminase (AST), glutamic pyruvic transaminase (ALT)<2.5xULN, which is allowed<5xULN in patients with liver metastasis	word_scores:cancer	liver metastasis	1.000
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: Serum creatinine ≤ 1.25xULN or calculated creatinine clearance ≥ 50mL/min	word_scores:clinical_variable	serum creatinine	1.000
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: Serum creatinine ≤ 1.25xULN or calculated creatinine clearance ≥ 50mL/min	word_scores:clinical_variable	calculated creatinine clearance	1.000
NCT04348032	exclusion	Have received more than two chemotherapy regimens in the past	word_scores:treatment	chemotherapy	1.000	Drug Therapy	E02.319	1.000
NCT04348032	exclusion	other malignant tumors have occurred within 5 years (except adequately treated cervical carcinoma in situ or skin squamous cell carcinoma, or controlled basal cell carcinoma of the skin)	word_scores:cancer	malignant tumors	1.000
NCT04348032	exclusion	other malignant tumors have occurred within 5 years (except adequately treated cervical carcinoma in situ or skin squamous cell carcinoma, or controlled basal cell carcinoma of the skin)	word_scores:cancer	cervical carcinoma situ	1.000	Cancer of the Uterine Cervix	C04.588.945.418.948.850|C13.351.500.852.593.131|C13.351.500.852.762.850|C13.351.937.418.875.850	1.000
NCT04348032	exclusion	other malignant tumors have occurred within 5 years (except adequately treated cervical carcinoma in situ or skin squamous cell carcinoma, or controlled basal cell carcinoma of the skin)	word_scores:cancer	skin squamous cell carcinoma	1.000
NCT04348032	exclusion	other malignant tumors have occurred within 5 years (except adequately treated cervical carcinoma in situ or skin squamous cell carcinoma, or controlled basal cell carcinoma of the skin)	word_scores:cancer	basal cell carcinoma skin	1.000	Carcinoma, Basal Cell	C04.557.470.200.165|C04.557.470.565.165	0.773
NCT04348032	exclusion	Patients with hypertension that cannot be reduced to normal range after antihypertensive treatment (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90 mmHg)	word_scores:chronic_disease	hypertension	1.000	Hypertension	C14.907.489	1.000
NCT04348032	exclusion	Patients with hypertension that cannot be reduced to normal range after antihypertensive treatment (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90 mmHg)	word_scores:treatment	antihypertensive treatment	1.000	Antihypertensive Agents	D27.505.954.411.162	0.929
NCT04348032	exclusion	Patients with hypertension that cannot be reduced to normal range after antihypertensive treatment (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90 mmHg)	word_scores:clinical_variable	systolic blood pressure	1.000
NCT04348032	exclusion	Patients with hypertension that cannot be reduced to normal range after antihypertensive treatment (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90 mmHg)	word_scores:clinical_variable	diastolic blood pressure	1.000
NCT04348032	exclusion	Suffer from myocardial ischemia or myocardial infarction above II grade and poorly controlled arrhythmias (including QTc interval ≥ 470ms in females)	word_scores:chronic_disease	suffer	1.000
NCT04348032	exclusion	Suffer from myocardial ischemia or myocardial infarction above II grade and poorly controlled arrhythmias (including QTc interval ≥ 470ms in females)	word_scores:chronic_disease	myocardial ischemia	1.000	Myocardial Ischemia	C14.280.647|C14.907.585	1.000
NCT04348032	exclusion	Suffer from myocardial ischemia or myocardial infarction above II grade and poorly controlled arrhythmias (including QTc interval ≥ 470ms in females)	word_scores:chronic_disease	myocardial infarction	1.000	Myocardial Infarction	C14.280.647.500|C14.907.585.500|C23.550.513.355.750|C23.550.717.489.750	1.000
NCT04348032	exclusion	Suffer from myocardial ischemia or myocardial infarction above II grade and poorly controlled arrhythmias (including QTc interval ≥ 470ms in females)	word_scores:chronic_disease	arrhythmias	1.000	Arrhythmias, Cardiac	C14.280.067|C23.550.073	0.875
NCT04348032	exclusion	Suffer from myocardial ischemia or myocardial infarction above II grade and poorly controlled arrhythmias (including QTc interval ≥ 470ms in females)	word_scores:clinical_variable	qtc interval	1.000
NCT04348032	exclusion	Suffer from myocardial ischemia or myocardial infarction above II grade and poorly controlled arrhythmias (including QTc interval ≥ 470ms in females)	word_scores:gender	females	1.000	Women	M01.975	1.000
NCT04348032	exclusion	According to the NYHA standard, there were previous or present cardiac insufficiency of grade II or above, or color Doppler echocardiography showed that the left ventricular ejection fraction ((LVEF)) was less than 50% or the lower limit of the normal value	word_scores:chronic_disease	cardiac insufficiency	1.000
NCT04348032	exclusion	According to the NYHA standard, there were previous or present cardiac insufficiency of grade II or above, or color Doppler echocardiography showed that the left ventricular ejection fraction ((LVEF)) was less than 50% or the lower limit of the normal value	word_scores:treatment	color doppler echocardiography	1.000	Echocardiography, Doppler, Color	E01.370.350.130.750.220.220|E01.370.350.850.220.220.220|E01.370.350.850.850.220.220|E01.370.350.850.850.850.850.220|E01.370.370.380.220.220.220	1.000
NCT04348032	exclusion	According to the NYHA standard, there were previous or present cardiac insufficiency of grade II or above, or color Doppler echocardiography showed that the left ventricular ejection fraction ((LVEF)) was less than 50% or the lower limit of the normal value	word_scores:clinical_variable	left ventricular ejection fraction	1.000
NCT04348032	exclusion	Abnormal coagulation function (INR>1.5 or prothrombin time (PT) > ULN+4 seconds or APTT>1.5xULN), with bleeding tendency or undergoing thrombolytic or anticoagulant therapy	word_scores:clinical_variable	prothrombin time	1.000	Prothrombin Time	E01.370.225.625.115.610|E05.200.625.115.610|G09.188.680	1.000
NCT04348032	exclusion	Abnormal coagulation function (INR>1.5 or prothrombin time (PT) > ULN+4 seconds or APTT>1.5xULN), with bleeding tendency or undergoing thrombolytic or anticoagulant therapy	word_scores:treatment	thrombolytic	1.000	Thrombolytic Therapy	E02.319.913	1.000
NCT04348032	exclusion	Abnormal coagulation function (INR>1.5 or prothrombin time (PT) > ULN+4 seconds or APTT>1.5xULN), with bleeding tendency or undergoing thrombolytic or anticoagulant therapy	word_scores:treatment	anticoagulant therapy	1.000	Anticoagulants	D27.505.954.502.119	1.000
NCT04348032	exclusion	There were significant clinical bleeding symptoms or definite bleeding tendency in the first 3 months, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood or above, or suffering from vasculitis	word_scores:chronic_disease	gastrointestinal bleeding	1.000	Gastrointestinal Tract	A03.556	1.000
NCT04348032	exclusion	There were significant clinical bleeding symptoms or definite bleeding tendency in the first 3 months, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood or above, or suffering from vasculitis	word_scores:chronic_disease	hemorrhagic gastric ulcer	1.000
NCT04348032	exclusion	There were significant clinical bleeding symptoms or definite bleeding tendency in the first 3 months, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood or above, or suffering from vasculitis	word_scores:chronic_disease	vasculitis	1.000	Vasculitis	C14.907.940	1.000
NCT04348032	exclusion	Major surgical operations or severe traumatic injuries, fractures or ulcers occurred within the first 4 weeks of randomization	word_scores:treatment	major surgical operations	1.000
NCT04348032	exclusion	Major surgical operations or severe traumatic injuries, fractures or ulcers occurred within the first 4 weeks of randomization	word_scores:chronic_disease	fractures	1.000
NCT04348032	exclusion	Major surgical operations or severe traumatic injuries, fractures or ulcers occurred within the first 4 weeks of randomization	word_scores:chronic_disease	ulcers	1.000	Ulcer	C23.550.891	1.000
NCT04348032	exclusion	There are significant factors affecting oral drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction	word_scores:treatment	oral drug absorption	1.000
NCT04348032	exclusion	There are significant factors affecting oral drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction	word_scores:chronic_disease	chronic diarrhea	1.000
NCT04348032	exclusion	There are significant factors affecting oral drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction	word_scores:chronic_disease	intestinal obstruction	1.000	Intestinal Obstruction	C06.405.469.531	1.000
NCT04348032	exclusion	Urine routine indicates urinary protein ≥++, or confirms 24-hour urinary protein ≥ 1.0g	word_scores:clinical_variable	urinary protein	1.000
NCT04348032	exclusion	Urine routine indicates urinary protein ≥++, or confirms 24-hour urinary protein ≥ 1.0g	word_scores:clinical_variable	24-hour urinary protein	1.000
NCT04348032	exclusion	Allergic or heterogeneous reactions to doxorubicin and / or related substances	word_scores:allergy_name	doxorubicin	1.000	Doxorubicin	D02.455.426.559.847.562.050.200.175|D04.615.562.050.200.175|D09.408.051.059.200.175	1.000
NCT04348032	exclusion	The cumulative dose of doxorubicin (including previous anthracycline, if any) is expected to reach or exceed 550 mg after 4 courses of doxorubicin liposome injection treatment	word_scores:treatment	doxorubicin	1.000	Doxorubicin	D02.455.426.559.847.562.050.200.175|D04.615.562.050.200.175|D09.408.051.059.200.175	1.000
NCT04348032	exclusion	The cumulative dose of doxorubicin (including previous anthracycline, if any) is expected to reach or exceed 550 mg after 4 courses of doxorubicin liposome injection treatment	word_scores:treatment	anthracycline	1.000	Anthracyclines	D02.455.426.559.847.562.050|D04.615.562.050|D09.408.051.059	0.909
NCT04348032	exclusion	The cumulative dose of doxorubicin (including previous anthracycline, if any) is expected to reach or exceed 550 mg after 4 courses of doxorubicin liposome injection treatment	word_scores:treatment	doxorubicin liposome injection treatment	1.000
NCT04348032	exclusion	Uncontrollable arrhythmias or electrocardiograms abnormalities determined by the lead researcher to be at risk	word_scores:chronic_disease	uncontrollable arrhythmias	1.000
NCT04348032	exclusion	Uncontrollable arrhythmias or electrocardiograms abnormalities determined by the lead researcher to be at risk	word_scores:chronic_disease	electrocardiograms abnormalities	1.000
NCT04348032	exclusion	A history of doxorubicin liposome therapy in recent half a year	word_scores:treatment	doxorubicin liposome therapy	1.000
NCT04348032	exclusion	Have previously received local radiotherapy of the pelvis or lower abdomen	word_scores:treatment	local radiotherapy	1.000
NCT04348006	inclusion	Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A: anemia, and B: bone lesions)	word_scores:cancer	multiple myeloma	1.000	Multiple Myeloma	C04.557.595.500|C14.907.454.460|C15.378.147.780.650|C15.378.463.515.460|C20.683.515.845|C20.683.780.650	1.000
NCT04348006	inclusion	Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A: anemia, and B: bone lesions)	word_scores:chronic_disease	hypercalcemia	1.000	Hypercalcemia	C18.452.174.451|C18.452.950.340	1.000
NCT04348006	inclusion	Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A: anemia, and B: bone lesions)	word_scores:chronic_disease	r	1.000
NCT04348006	inclusion	Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A: anemia, and B: bone lesions)	word_scores:chronic_disease	renal impairment	1.000	Kidney	A05.810.453	1.000
NCT04348006	inclusion	Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A: anemia, and B: bone lesions)	word_scores:chronic_disease	anemia	1.000	Anemia	C15.378.071	1.000
NCT04348006	exclusion	Smoldering MM	word_scores:cancer	smoldering multiple myeloma	1.000	Smoldering Multiple Myeloma	C04.834.794|C15.378.147.542.820|C15.378.147.780.838|C20.683.460.820|C20.683.780.838	1.000
NCT04347252	inclusion	Healthy, fasting glucose values < 6 mM, A1c < 6%, and no first degree family members with T2DM	word_scores:clinical_variable	fasting glucose values	1.000
NCT04347252	inclusion	Healthy, fasting glucose values < 6 mM, A1c < 6%, and no first degree family members with T2DM	word_scores:clinical_variable	a1c	1.000
NCT04347252	inclusion	Healthy, fasting glucose values < 6 mM, A1c < 6%, and no first degree family members with T2DM	word_scores:chronic_disease	t2dm	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:chronic_disease	active infectious	1.000	Factive	D03.633.100.612.250|D03.633.100.810.835.322.322	0.750
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:cancer	malignant	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:chronic_disease	inflammatory conditions	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:chronic_disease	unstable angina	1.000	Angina, Unstable	C14.280.647.187.150|C14.907.585.187.150|C23.888.592.612.233.500.150	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:chronic_disease	heart failure	1.000	Heart Failure	C14.280.434	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:chronic_disease	pulmonary disorders	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:chronic_disease	copd	1.000	Pulmonary Disease, Chronic Obstructive	C08.381.495.389	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:chronic_disease	asthma	1.000	Asthma	C08.127.108|C08.381.495.108|C08.674.095|C20.543.480.680.095	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:chronic_disease	malabsorptive gastrointestinal disease	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:chronic_disease	hepatic disease	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:chronic_disease	renal insufficiency	1.000	Renal Insufficiency	C12.777.419.780|C13.351.968.419.780	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:clinical_variable	egfr	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:chronic_disease	anemia	1.000	Anemia	C15.378.071	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:clinical_variable	hematocrit	1.000	Hematocrit	E01.370.225.625.400|E05.200.625.400|G09.188.370.374	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:pregnancy	pregnancy	1.000	Pregnancy	G08.686.784.769	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:treatment	glucocorticoids	1.000	Glucocorticoids	D06.472.040.543|D27.505.696.399.472.488	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:treatment	psychotropics	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:treatment	narcotics	1.000	Narcotics	D27.505.696.277.600|D27.505.696.663.850.014.760|D27.505.954.427.040.550|D27.505.954.427.210.600	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:treatment	metoclopramide	1.000	Metoclopramide	D02.065.277.573|D02.241.223.100.050.500.647|D02.241.223.100.100.510|D02.241.223.100.200.750|D02.241.223.100.300.350.625|D02.241.511.390.350.625|D02.455.426.559.389.127.020.937.647|D02.455.426.559.389.127.085.510|D02.455.426.559.389.127.250.750|D02.455.426.559.389.127.281.350.625|D02.455.426.559.389.657.654.638.625	1.000
NCT04344847	inclusion	All morbid obese patients with BMI more than 35	word_scores:chronic_disease	morbid obese	1.000
NCT04344847	exclusion	previous gastric surgery	word_scores:treatment	previous gastric surgery	1.000
NCT04344847	exclusion	patients with hiatus hernia	word_scores:chronic_disease	hiatus hernia	1.000	Hernia, Hiatal	C23.300.707.500.467	1.000
NCT04344678	inclusion	Eighty adult outpatients with the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of MDD based on a MINI Neuropsychiatric Interview (MINI) (American Psychiatric Association., 2000; Sheehan et al., 1998), without psychotic features and a total 17 item HAM-D score of at least 18 with item 1 (depressed mood) scored 2 or greater were eligible (Hamilton, 1960)	word_scores:clinical_variable	diagnostic statistical manual mental disorders-iv	1.000
NCT04344678	inclusion	Eighty adult outpatients with the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of MDD based on a MINI Neuropsychiatric Interview (MINI) (American Psychiatric Association., 2000; Sheehan et al., 1998), without psychotic features and a total 17 item HAM-D score of at least 18 with item 1 (depressed mood) scored 2 or greater were eligible (Hamilton, 1960)	word_scores:chronic_disease	mdd	1.000
NCT04344678	inclusion	Eighty adult outpatients with the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of MDD based on a MINI Neuropsychiatric Interview (MINI) (American Psychiatric Association., 2000; Sheehan et al., 1998), without psychotic features and a total 17 item HAM-D score of at least 18 with item 1 (depressed mood) scored 2 or greater were eligible (Hamilton, 1960)	word_scores:clinical_variable	mini neuropsychiatric interview	1.000
NCT04344678	inclusion	Eighty adult outpatients with the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of MDD based on a MINI Neuropsychiatric Interview (MINI) (American Psychiatric Association., 2000; Sheehan et al., 1998), without psychotic features and a total 17 item HAM-D score of at least 18 with item 1 (depressed mood) scored 2 or greater were eligible (Hamilton, 1960)	word_scores:clinical_variable	17 item ham-d score	1.000
NCT04344678	inclusion	Patients were requested to be free of all the psychotropic and anti-inflammatory medications for at least 4 weeks before participating in the study	word_scores:treatment	psychotropic	1.000
NCT04344678	inclusion	Patients were requested to be free of all the psychotropic and anti-inflammatory medications for at least 4 weeks before participating in the study	word_scores:treatment	anti-inflammatory medications	1.000
NCT04344678	exclusion	Patients with bipolar I or bipolar II disorder	word_scores:chronic_disease	bipolar i	1.000
NCT04344678	exclusion	Patients with bipolar I or bipolar II disorder	word_scores:chronic_disease	bipolar ii disorder	1.000	Bipolar Disorder	F03.084.500	0.812
NCT04344678	exclusion	Patients with personality disorders	word_scores:chronic_disease	personality disorders	1.000	Personality Disorders	F03.675	1.000
NCT04344678	exclusion	Patients with eating disorders	word_scores:chronic_disease	eating disorders	1.000	Eating Disorders	F03.400	1.000
NCT04344678	exclusion	Patients with history of seizures	word_scores:chronic_disease	seizures	1.000	Seizures	C10.597.742|C23.888.592.742	1.000
NCT04344678	exclusion	Patients with history of receiving Electroconvulsive therapy (ECT)	word_scores:treatment	electroconvulsive therapy	1.000	Electroconvulsive Therapy	F04.570.200.583|F04.669.224.300	1.000
NCT04344678	exclusion	Patients with inflammatory disorders	word_scores:chronic_disease	inflammatory disorders	1.000
NCT04344678	exclusion	Patients with allergy or contraindications to the used medications	word_scores:treatment	medications	1.000	Pharmaceutical Preparations	D26	0.875
NCT04344678	exclusion	Patients with finally pregnant or lactating females	word_scores:chronic_disease	finally pregnant	1.000
NCT04344678	exclusion	Patients with finally pregnant or lactating females	word_scores:gender	females	1.000	Women	M01.975	1.000
NCT04344678	exclusion	Cardiovascular disorders	word_scores:chronic_disease	cardiovascular disorders	1.000
NCT04344678	exclusion	Severe renal impairment: creatinine clearance of ≤ 25 ml/min	word_scores:chronic_disease	severe renal impairment	1.000	Kidney	A05.810.453	1.000
NCT04344678	exclusion	Severe renal impairment: creatinine clearance of ≤ 25 ml/min	word_scores:clinical_variable	creatinine clearance	1.000
NCT04344678	exclusion	Moderate or severe hepatic impairment	word_scores:chronic_disease	hepatic impairment	1.000	Hepatica	B01.650.940.800.575.912.250.836.750	0.800
NCT04344470	inclusion	Right-handed (tested by the Edinburg handedness inventory)	word_scores:clinical_variable	edinburg handedness inventory	1.000
NCT04344470	inclusion	Fluent in English	word_scores:language_fluency	fluent english	1.000	Language Fluency, English	LF01.01	0.769
NCT04344470	exclusion	Illegal drug use within the past 6 months based on history alone. The intent is to exclude those with drug use that may affect study results	word_scores:treatment	illegal drug	1.000
NCT04344470	exclusion	Self-reported consumption of >14 alcoholic drinks/week for a man and >7 alcoholic drinks/week for a woman	word_scores:gender	man	1.000	Humans|Men	B01.050.150.900.649.313.988.400.112.400.400|M01.390	1.000
NCT04344470	exclusion	Self-reported consumption of >14 alcoholic drinks/week for a man and >7 alcoholic drinks/week for a woman	word_scores:gender	woman	1.000	Women	M01.975	1.000
NCT04344470	exclusion	Abnormal findings on neurological examination	word_scores:treatment	neurological examination	1.000	Neurologic Examination	E01.370.376.550|E01.370.600.550	1.000
NCT04344470	exclusion	History of current brain tumor, stroke, head trauma with loss of consciousness, epilepsy, or seizures	word_scores:cancer	brain tumor	1.000	Brain Neoplasms	C04.588.614.250.195|C10.228.140.211|C10.551.240.250	1.000
NCT04344470	exclusion	History of current brain tumor, stroke, head trauma with loss of consciousness, epilepsy, or seizures	word_scores:chronic_disease	stroke	1.000	Stroke	C10.228.140.300.775|C14.907.253.855	1.000
NCT04344470	exclusion	History of current brain tumor, stroke, head trauma with loss of consciousness, epilepsy, or seizures	word_scores:chronic_disease	head trauma	1.000	Craniocerebral Trauma	C10.900.300|C26.915.300	1.000
NCT04344470	exclusion	History of current brain tumor, stroke, head trauma with loss of consciousness, epilepsy, or seizures	word_scores:chronic_disease	epilepsy	1.000	Epilepsy	C10.228.140.490	1.000
NCT04344470	exclusion	History of current brain tumor, stroke, head trauma with loss of consciousness, epilepsy, or seizures	word_scores:chronic_disease	seizures	1.000	Seizures	C10.597.742|C23.888.592.742	1.000
NCT04344470	exclusion	Current episode of major depression or any major psychiatric illness	word_scores:chronic_disease	major depression	1.000
NCT04344470	exclusion	Current episode of major depression or any major psychiatric illness	word_scores:chronic_disease	major psychiatric illness	1.000
NCT04343391	inclusion	Emotional Disorder	word_scores:chronic_disease	emotional disorder	1.000
NCT04343391	exclusion	Severe mental disorder	word_scores:chronic_disease	severe mental disorder	1.000	Mental Disorder		1.000
NCT04343391	exclusion	Substance use disorder	word_scores:chronic_disease	substance use disorder	1.000	Substance Use Disorders	C25.775|F03.900	1.000
NCT04343391	exclusion	Severe depression	word_scores:chronic_disease	severe depression	1.000	Depression	F01.145.126.350	1.000
NCT04343014	inclusion	ASA graded I~II class	word_scores:clinical_variable	asa graded	1.000
NCT04343014	inclusion	scheduled for elective surgery requiring orotracheal intubation	word_scores:treatment	elective surgery	1.000
NCT04343014	inclusion	scheduled for elective surgery requiring orotracheal intubation	word_scores:treatment	orotracheal intubation	1.000
NCT04343014	exclusion	with organ transplant operations	word_scores:treatment	organ transplant	1.000	Organ Transplants	A01.941	1.000
NCT04343014	exclusion	with thoracic and cardiac vascular surgery	word_scores:treatment	cardiac vascular surgery	1.000
NCT04343014	exclusion	with severe cadiac or pulmonary disease	word_scores:chronic_disease	pulmonary disease	1.000	Lung Diseases	C08.381	1.000
NCT04342793	inclusion	Men or women ages 19 and over, under 75 years of age	word_scores:gender	women	1.000	Women	M01.975	1.000
NCT04342793	inclusion	Patients diagnosed with NAFLD on abdominal ultrasonography and MRI	word_scores:chronic_disease	nafld	1.000	Non-alcoholic Fatty Liver Disease	C06.552.241.519	1.000
NCT04342793	inclusion	Patients diagnosed with NAFLD on abdominal ultrasonography and MRI	word_scores:treatment	abdominal ultrasonography	1.000
NCT04342793	inclusion	Patients diagnosed with NAFLD on abdominal ultrasonography and MRI	word_scores:treatment	magnetic resonance imaging	1.000	Magnetic Resonance Imaging	E01.370.350.825.500	1.000
NCT04342793	inclusion	Patients show presence of hepatic fat fraction as defined by ≥ 8% on MRI-PDFF and liver stiffness as defined by ≥ 2.5 kPa on MRE at Screening	word_scores:clinical_variable	hepatic fat fraction	1.000
NCT04342793	exclusion	Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease	word_scores:chronic_disease	chronic liver disease	1.000
NCT04342793	exclusion	Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease	word_scores:chronic_disease	hemochromatosis	1.000	Hemochromatosis	C16.320.565.618.337|C18.452.565.500.480|C18.452.648.618.337	1.000
NCT04342793	exclusion	Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease	word_scores:cancer	liver cancer	1.000	Cancer of Liver|Carcinoma, Hepatocellular	C04.557.470.200.025.255|C04.588.274.623|C04.588.274.623.160|C06.301.623|C06.301.623.160|C06.552.697|C06.552.697.160	1.000
NCT04342793	exclusion	Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease	word_scores:chronic_disease	autoimmune liver disease	1.000
NCT04342793	exclusion	Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease	word_scores:chronic_disease	viral hepatitis a b	1.000	Hepatitis, Viral, Human	C01.925.440|C06.552.380.705	0.857
NCT04342793	exclusion	Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease	word_scores:chronic_disease	viral hepatitis a b	1.000	Hepatitis B	C01.925.256.430.400|C01.925.440.435|C06.552.380.705.437	1.000
NCT04342793	exclusion	Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease	word_scores:chronic_disease	alcoholic liver disease	1.000	Liver Diseases, Alcoholic	C06.552.645|C25.775.100.087.645	1.000
NCT04342793	exclusion	Uncontrolled diabetes mellitus as defined by a HbA1c ≥ 9.0％ at Screening	word_scores:chronic_disease	diabetes mellitus	1.000	Diabetes Mellitus	C18.452.394.750|C19.246	1.000
NCT04342793	exclusion	Uncontrolled diabetes mellitus as defined by a HbA1c ≥ 9.0％ at Screening	word_scores:clinical_variable	hba1c	1.000
NCT04342793	exclusion	Pregnant or lactating women	word_scores:pregnancy	pregnant	1.000	Pregnancy	G08.686.784.769	1.000
NCT04342793	exclusion	Pregnant or lactating women	word_scores:gender	women	1.000	Women	M01.975	1.000
